Parkinson Society Canada is looking to make a stronger case to the Canadian Agency for Drugs and Technologies in Health (CADTH) on the need for Canadians affected by Parkinson’s to have access to the new Parkinson’s treatment NEUPRO®.
We will be interviewing members of our community about their experiences with this treatment. Whether you are directly affected, or you are a caregiver of someone with Parkinson’s and taking NEUPRO®, your input is crucial in our efforts to improve access to this treatment.
The NEUPRO® patch is a dopamine agonist used for the treatment of Parkinson’s disease and restless legs syndrome. It works by delivering a steady stream of Parkinson’s medication over a 24-hour period through the surface of your skin from the once-a-day applied patch, effectively diminishing the need for repeated dosing throughout the day.
If you would like to share your experiences on NEUPRO®, please contact us at email@example.com and provide your name, email address and a phone number where you can be reached. We will then contact you to arrange a time to speak with you at your convenience. These confidential discussions should take about 10 to 20 minutes.
Parkinson Society Canada thanks all members of our community for contributing their feedback on the use of NEUPRO®. The results of our submission to CADTH will be shared with you in the near future.